Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, and OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, are pleased to announce they have entered into a research collaboration to combine Avacta’s Affimer protein platform with OncoSec’s gene delivery technology ImmunoPulse®.
Beckman Coulter Life Sciences launched a family of FormaPure reagent kits for extracting nucleic acid from often challenging formalin-fixed, paraffin-embedded (FFPE) tissues. FormaPure reagent kits represent a single chemistry system designed and optimized for use in next-generation sequencing (NGS) and other downstream applications, including qPCR/ddPCR/PCR.
IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, announced today that it has signed an agreement with Sanofi to discover antibodies using IONTAS’ proprietary Mammalian Display Technology.
10x Genomics, Inc., a company focused on accelerating genomic discovery, today launched a new version of their de novo assembly solution to provide the fastest most cost-effective solution for creating high-quality de novo assemblies at scale for plants and animals.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of the NGC Fraction Collector. When used with the NGC Chromatography System, the NGC Fraction Collector provides the flexibility and collection capacity needed for any application, from discovery to scale up.
Desktop Genetics Ltd (DTG), a biotech company globally recognised for its leadership in gene-editing bioinformatics, acquired exclusive worldwide licensing rights for TIDE (Tracking of Indels by DEcomposition), from the Netherlands Cancer Institute (NKI). The TIDE technology will allow investigators to quantitatively assess genome editing on the DESKGEN Cloud, the free CRISPR design software from DTG.